Mizuho Securities Reiterates Buy Rating, $12 PT on IN8bio (INAB), Sees Latest Presentations as "Supportive of INAB's Drug-resistant Immunotherapy Platform"
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: INAB) | Delayed: 0.93 -0.02 (2.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.95 | 52 Week High | $ | |||
| Open | $0.94 | 52 Week Low | $ | |||
| Day High | $0.97 | P/E | N/A | |||
| Day Low | $0.92 | EPS | $ | |||
| Volume | 107,527 | |||||
